No Data
Protagonist Therapeutics Participates in a Conference Call With JPMorgan
TD Cowen Initiates Protagonist Therapeutics(PTGX.US) With Buy Rating, Announces Target Price $65
Express News | Protagonist Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating; Target Price $65
The 8.6% Return This Week Takes Protagonist Therapeutics' (NASDAQ:PTGX) Shareholders Five-year Gains to 231%
H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $50
Analysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), Belite Bio, Inc. ADR (BLTE) and Protagonist Therapeutics (PTGX)
Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In GrowthNo Data
No Data
